Recently we reported that recombinant Hsp70 delivered to tumor loci using hydrogel applications also delayed tumor growth and reduced the number of arginase-1-positive TAMs with a similar efficacy28, but the quantity of Hsp70 delivered with the EVs was 1000-fold lower than with the Hsp70-hydrogel. The gene discussed is ARG1; the disease is neoplasm.